3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors

NCT00079014 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

NIH

Sponsor class

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: triapine
DRUG: doxorubicin hydrochloride
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)